Welcome to our dedicated page for Atyr Pharma SEC filings (Ticker: ATYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
aTyr Pharma, Inc. filings document a clinical-stage biotechnology issuer focused on tRNA synthetase-derived medicines and the efzofitimod program for interstitial lung disease. Form 8-K reports furnish quarterly and annual results, corporate updates, and clinical-study disclosures, including EFZO-FIT results in pulmonary sarcoidosis.
Proxy materials describe board elections, stockholder meeting proposals, executive compensation, equity awards, and governance practices. The filing record also reflects capital-structure and stock-based compensation disclosures relevant to a development-stage biotechnology company funding research, clinical trials, and manufacturing activities for its lead program.
aTyr Pharma, Inc. received an additional 180-day period from Nasdaq to regain compliance with the exchange’s minimum bid price requirement for continued listing. The company now has until November 30, 2026 for its stock to close at or above $1.00 for at least 10 consecutive business days.
The extension was granted because aTyr meets other Nasdaq Capital Market listing standards, including market value of publicly held shares, and has stated its intention to cure the deficiency, potentially through a reverse stock split. The company’s shares remain listed while it monitors its stock price and evaluates options.
ATYR PHARMA INC reports an Amendment No. 14 to a Schedule 13G/A disclosing that FMR LLC beneficially owns 5,935,900 shares of Common Stock, representing 6.1% of the class. The filing lists voting and dispositive powers attributed to FMR LLC and Abigail P. Johnson and references an exhibit concerning a 13d-1(k) agreement.
aTyr Pharma furnished an investor presentation outlining updated clinical data and plans for its lead biologic immunomodulator efzofitimod in pulmonary sarcoidosis and other interstitial lung diseases. The Phase 3 EFZO-FIT trial, the largest interventional pulmonary sarcoidosis study to date, did not meet its primary endpoint of reducing oral corticosteroid dose versus placebo, but showed higher steroid-free rates and improvements in multiple quality-of-life measures at the 5 mg/kg dose while maintaining lung function and a generally favorable safety profile.
The company describes FDA feedback from a Type C meeting supporting forced vital capacity (FVC) and KSQ-L as clinically meaningful endpoints, with FVC selected as the primary endpoint for a new Phase 3 trial (C-006) in patients with restrictive pulmonary sarcoidosis. Efzofitimod is also being tested in the Phase 2 EFZO-CONNECT study for systemic sclerosis-associated ILD and supported by a broader tRNA synthetase–based pipeline, including preclinical fibrosis candidate ATYR0101 and a proprietary tRNA synthetase library targeting inflammatory and fibrotic diseases.
aTyr Pharma director Paul Schimmel reported an open-market purchase of 100,000 shares of aTyr Pharma common stock on May 27, 2026 at a weighted average price of $0.4963 per share.
According to the filing, these shares were bought in multiple trades between $0.4907 and $0.50 per share and are held indirectly through entities associated with Schimmel as noted in the footnotes.
aTyr Pharma, Inc. reported first quarter 2026 results and outlined next steps for its lead drug efzofitimod in interstitial lung disease. The company plans to submit an IND in June 2026 for a global Phase 3 pulmonary sarcoidosis study and is on track to complete enrollment in its Phase 2 EFZO-CONNECT SSc-ILD trial in the first half of 2026.
aTyr ended the quarter with $68.3 million in cash, cash equivalents, restricted cash and investments. Net loss attributable to aTyr was $10.8 million, compared with $14.9 million a year earlier, with net loss per share of $0.11 versus $0.17 in 2025. Research and development expenses were $7.3 million and general and administrative expenses were $4.1 million for the quarter.
aTyr Pharma director Timothy Coughlin received a compensatory stock option grant, giving him the right to acquire 50,000 shares of common stock. The option has an exercise price of $0.95 per share and expires on May 11, 2036.
According to the company’s non-employee director compensation policy, the option vests in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Coughlin continues to serve on the board. After this grant, he holds stock options covering 50,000 shares directly.
aTYR Pharma director Eric Benevich received a new stock option grant. On May 11, 2026, he was awarded options to buy 50,000 shares of aTYR Pharma common stock at an exercise price of $0.95 per share. These options were granted under the company’s non-employee director compensation policy.
The option vests in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, provided he continues serving on the Board of Directors. Following this grant, he holds 50,000 stock options directly.
aTyr Pharma director Jane A. Gross received a grant of stock options covering 50,000 shares of Common Stock. The options have an exercise price of $0.95 per share and were awarded at no upfront cost as a compensation grant.
The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Gross continues to serve on the Board. After this grant, she holds 50,000 stock options directly according to the filing.
aTYR PHARMA INC director Svetlana Lucas received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $0.95 per share and expire on May 11, 2036.
The grant was made under the company’s non-employee director compensation policy. The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving on the board. This is a compensation-related award rather than an open-market transaction.